Filing Flows › Iovance Biotherapeutics (IOVA) › Q3 2026 › vs Q3 2025
Iovance Biotherapeutics (IOVA) Q3 2026 vs Q3 2025 (year over year)
Iovance Biotherapeutics's revenue rose $54.0M (+80%) from $67.5M in Q3 2025 to $121M in Q3 2026.
Iovance Biotherapeutics, Q3 2026: revenue $121M (+80% year over year), operating margin -19.7%, net loss $22.3M, operating cash flow −$4.5M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $121M | $67.5M | $54.0M | +80% |
| Other income, net | $2.3M | $1.2M | $1.1M | +86% |
| Net loss | $22.3M | $91.3M | −$69.0M | -76% |
| Costs & expenses | $146M | $162M | −$16.3M | -10% |
| Operating costs | $145M | $162M | −$16.9M | -10% |
| Income tax | $614K | −$2.4M | $3.0M | — |
| Cost of revenue | $48.0M | $38.5M | $9.6M | +25% |
| Research & development | $49.3M | $75.2M | −$25.8M | -34% |
| General & admin | $38.6M | $34.6M | $4.0M | +12% |
| Other operating costs | $9.5M | $14.2M | −$4.7M | -33% |
| Operating cash sources | $22.3M | $91.3M | −$69.0M | -76% |
| Depreciation & amortization | $3.8M | $3.2M | $609K | +19% |
| Share-based compensation | $11.8M | $11.9M | −$67K | -0.6% |
| Working capital & other | $2.2M | −$2.5M | $4.7M | — |
| Cash used in operations | $4.5M | $78.7M | −$74.2M | -94% |
| Net loss absorbed | $22.3M | $91.3M | −$69.0M | -76% |
Questions
How much did Iovance Biotherapeutics's revenue grow year over year in Q3 2026?
Iovance Biotherapeutics's revenue rose $54.0M (+80%) from $67.5M in Q3 2025 to $121M in Q3 2026.